Table 3

Studies regarding impact of dosing intermittency on treatment efficacy in tuberculosis with isoniazid resistance

Authors, year of publicationMeasures of treatment efficacySource of study materialsStudy designMain findingsStrengthsWeaknessesRisk of bias
Menzies et al, 200946Failure, relapse, acquired drug resistanceMultiple countriesSystematic review and meta-analysis*Among TB patients with initial mono-resistance to isoniazid, partially intermittent treatment with daily initial phase reduces the rates of failure, relapses and acquired drug resistance.The study clearly addressed a focused question with good coverage on methodology and assessment of study quality. Literature search was sufficiently rigorous.There was considerable heterogeneity across studies.Low
Escalante et al, 200147RelapseUSARetrospective cohort analysisTwice-weekly treatment was associated with relapse among subjects with resistance to isoniazid. Thrice-weekly and daily treatment showed similar efficacy.The study clearly addressed a focused question in a well-defined cohort. Outcomes were clearly defined, with reliable assessment of exposure.Assessment of outcome was not blind. No comparison was made between participants and non-participants. Main potential confounders were not considered. CIs were not provided.High
  • * Articles identified by the literature search and included in systematic reviews identified by the current review are shown in appendix 3 in the online supplement.

  • TB, tuberculosis.